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FDA’s Process Analytical Technology (PAT) aims at “improving the pharmaceutical development, 
manufacturing and quality assurance trough innovation in product and process development, process 
analysis and process control” [1-2]. Using Raman and Near Infrared (NIR) spectroscopy as PAT tools, 
3 critical quality attributes of a silicone-based drug reservoir were studied. First, the crosslinking 
process was monitored at different temperatures with NIR spectroscopy. Principal Component 
Analysis (PCA) and Conformity Indexes (CIs) were performed on the collected data to visualize the 
spectral variations occurring during the process. Using CI, Figure (a) depicts the crosslinking kinetic of 
a sample thermostated at 80 °C. The process complet ion time was determined when the CI of the 
sample was close to 0, meaning that the difference between a crosslinked and an uncrosslinked 
sample was minimal. Second, the Active Pharmaceutical Ingredient (API) homogeneity in the reservoir 
was checked with Raman spectroscopy (mapping) (Figure (b)). Finally, a NIR model able to quantify 
the API in the drug reservoir was developed. An HPLC method was used as the reference method. 
Partial Least Squares (PLS) regression on the calibration set was performed to build prediction 
models of which the ability to quantify accurately was tested with an external validation set. The 1.2 % 
RMSEP of the NIR model indicated the global accuracy of the model. The accuracy profile based on 
tolerance intervals was used to generate a complete validation report [3]. Figure (c) displays the 
accuracy profile based on the external validation results. The 95 % tolerance interval calculated on the 
validation results (dashed blue lines) is included within the ±5 % acceptance limits (dotted black lines). 
Therefore, each future result will have a relative error below ±5 % with a probability of at least 95 %. In 
conclusion, 3 critical quality attributes of silicone-based drug reservoirs were quickly and efficiently 
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